JP2006223304A5 - - Google Patents

Download PDF

Info

Publication number
JP2006223304A5
JP2006223304A5 JP2006024604A JP2006024604A JP2006223304A5 JP 2006223304 A5 JP2006223304 A5 JP 2006223304A5 JP 2006024604 A JP2006024604 A JP 2006024604A JP 2006024604 A JP2006024604 A JP 2006024604A JP 2006223304 A5 JP2006223304 A5 JP 2006223304A5
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
polypeptide
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006024604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006223304A (ja
Filing date
Publication date
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/en
Priority claimed from PCT/US2001/017092 external-priority patent/WO2001092331A2/en
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/en
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/en
Priority claimed from PCT/US2001/021066 external-priority patent/WO2002008288A2/en
Priority claimed from PCT/US2001/021735 external-priority patent/WO2002008284A2/en
Application filed filed Critical
Publication of JP2006223304A publication Critical patent/JP2006223304A/ja
Publication of JP2006223304A5 publication Critical patent/JP2006223304A5/ja
Pending legal-status Critical Current

Links

JP2006024604A 2000-09-01 2006-02-01 分泌及び膜貫通ポリペプチドとそれをコードする核酸 Pending JP2006223304A (ja)

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US22989600P 2000-09-01 2000-09-01
US23062100P 2000-09-05 2000-09-05
US23514700P 2000-09-22 2000-09-22
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
US26187801P 2001-01-12 2001-01-12
US26193901P 2001-01-16 2001-01-16
US26215001P 2001-01-16 2001-01-16
US26191001P 2001-01-16 2001-01-16
US26439501P 2001-01-25 2001-01-25
US26642101P 2001-02-02 2001-02-02
US26762301P 2001-02-09 2001-02-09
PCT/US2001/006520 WO2001068848A2 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US27439901P 2001-03-09 2001-03-09
US28098201P 2001-04-03 2001-04-03
US28219901P 2001-04-04 2001-04-04
US28212901P 2001-04-04 2001-04-04
US29058901P 2001-05-09 2001-05-09
PCT/US2001/017092 WO2001092331A2 (en) 2000-05-30 2001-05-25 Compositions and methods for the treatment of immune related diseases
PCT/US2001/017800 WO2001093983A1 (en) 2000-06-02 2001-06-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/019692 WO2002000690A2 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PCT/US2001/021066 WO2002008288A2 (en) 2000-07-20 2001-06-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/021735 WO2002008284A2 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002529483A Division JP4451059B2 (ja) 2000-09-01 2001-08-29 分泌及び膜貫通ポリペプチドとそれをコードする核酸

Publications (2)

Publication Number Publication Date
JP2006223304A JP2006223304A (ja) 2006-08-31
JP2006223304A5 true JP2006223304A5 (enExample) 2008-10-09

Family

ID=27585542

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002529483A Expired - Lifetime JP4451059B2 (ja) 2000-09-01 2001-08-29 分泌及び膜貫通ポリペプチドとそれをコードする核酸
JP2006024604A Pending JP2006223304A (ja) 2000-09-01 2006-02-01 分泌及び膜貫通ポリペプチドとそれをコードする核酸

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002529483A Expired - Lifetime JP4451059B2 (ja) 2000-09-01 2001-08-29 分泌及び膜貫通ポリペプチドとそれをコードする核酸

Country Status (5)

Country Link
EP (1) EP1341814A2 (enExample)
JP (2) JP4451059B2 (enExample)
AU (2) AU2002216610A1 (enExample)
CA (2) CA2421056A1 (enExample)
WO (1) WO2002024888A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP4813660B2 (ja) 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
EP1666494A1 (en) * 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412110A1 (en) * 2000-06-19 2001-12-27 F. Hoffmann-La Roche Ag Osteolevin gene polymorphisms
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7094570B2 (en) 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
EP1404831A2 (en) 2001-01-12 2004-04-07 Genetics Institute, LLC Type 2 cytokine receptor and nucleic acids encoding same
AU2002325333B2 (en) * 2001-07-19 2008-04-03 Innate Pharma NTB-A, a surface molecule involved in natural killer cells activity
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
FR2844713A1 (fr) * 2002-09-25 2004-03-26 Exonhit Therapeutics Sa Nouvelle cible de l'angiogenese et utilisations
AU2003269557A1 (en) * 2002-10-18 2004-05-04 Lg Life Sciences Ltd. Gene families associated with cancers
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
WO2011051271A2 (en) 2009-10-26 2011-05-05 Externautics S.P.A. Prostate tumor markers and methods of use thereof
EP2494361B2 (en) 2009-10-26 2019-01-09 Externautics S.p.A. Ovary tumor markers and methods of use thereof
EP2383578A1 (en) * 2010-04-30 2011-11-02 Externautics S.p.A. Tumor marker and methods of use thereof
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EP2681242B1 (en) 2011-03-01 2018-01-24 Amgen Inc. Sclerostin and dkk-1 bispecific binding agents
EP2688910B1 (en) 2011-03-25 2019-05-29 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
EP2797953B1 (en) 2011-12-28 2020-06-03 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CA2893977C (en) 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
HRP20260414T1 (hr) 2018-03-30 2026-05-08 Amgen Inc. C-terminalne varijante protutijela

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
WO1999063088A2 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Membrane-bound proteins and nucleic acids encoding the same
CA2283299A1 (en) * 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
AU6777298A (en) * 1997-03-25 1998-10-20 Genetics Institute Inc. Secreted proteins and polynucleotides encoding them
DE19817557A1 (de) * 1998-04-09 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Ovartumorgewebe
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU3774300A (en) * 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Similar Documents

Publication Publication Date Title
JP2006068016A5 (enExample)
JP2006081548A5 (enExample)
JP2005253469A5 (enExample)
JP2005046146A5 (enExample)
JP2012152218A5 (enExample)
JP2005245460A5 (enExample)
JP2010162016A5 (enExample)
JP2004526412A5 (enExample)
JP2006516195A5 (enExample)
RU2012132442A (ru) Антитело к cd27
JP2012115275A5 (enExample)
JP2005027667A5 (enExample)
CA2503125A1 (en) Novel composition and methods for the treatment of immune related diseases
IL297111A (en) Peptide labels and binding partners
CN110964110B (zh) 抗EGFR人源化的单域抗体、Fc融合蛋白、重链Fab蛋白及其应用
JP2005518212A5 (enExample)
CN120230198A (zh) 抗nmp22的单克隆抗体及其制备方法和用途
JP2006521082A5 (enExample)
CN116041526A (zh) 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用
JPH1066585A5 (enExample)
JP7117088B2 (ja) 抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
JP2006521810A5 (enExample)
AU2010319615B2 (en) Glycosyl transferase from Chinese hamster and related methods
WO2018212468A1 (ko) 소수성 테일 도메인이 제거된 먹장어 유래 VLRB 단백질에 마우스 항체 유래 Fｃ 도메인이 연결된 융합 단백질 및 이의 용도
JP2006518582A5 (enExample)